AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16043735 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metformin (1.5-3.0 mg/day)
Number of subjects: 57
Study 11796175 — intervention group
Group type: EXPERIMENTAL
Intervention: voglibose
Number of subjects: 30
Study 11796175 — intervention group
Group type: EXPERIMENTAL
Intervention: acarbose
Number of subjects: 30
Study 10048120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide (U5, U20, U40, U80 ng/kg/min)
Number of subjects: 176
Study 10048120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (U0)
Number of subjects: 176
Study 7484129 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation and walking-cast for 5 weeks
Number of subjects: 79
Study 7484129 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking-cast alone
Number of subjects: 79
Study 7484129 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bandage
Number of subjects: 79
Study 2378290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological performance index (alcoholics who resumed drinking)
Number of subjects: 103
Study 2378290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological performance index (abstainers)
Number of subjects: 103
Study 2378290 — intervention group
Group type: COMPARATOR
Intervention: Neuropsychological performance index (nonalcoholics)
Number of subjects: 103
Study 2378290 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms, ADD, and performance index
Number of subjects: 103
Study 2378290 — intervention group
Group type: EXPERIMENTAL
Intervention: Retest performance (all groups)
Number of subjects: 103
Study 312709 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 121
Study 312709 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 121
Study 31179546 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (three doses: 0, 2, 6 months)
Number of subjects: 0
Study 30557108 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shockwave therapy (ESWT) with standard care
Number of subjects: 336
Study 30557108 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment with standard care
Number of subjects: 336
Study 26935044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 250 mg orally for the first 12 weeks
Number of subjects: 70
Study 26935044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 70
Study 26935044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22497849 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina
Number of subjects: 66
Study 22497849 — intervention group
Group type: COMPARATOR
Intervention: Silymarin
Number of subjects: 66
Study 20580827 — intervention group
Group type: EXPERIMENTAL
Intervention: lamotrigine
Number of subjects: 28
Study 20580827 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 17908974 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + imatinib
Number of subjects: 144
Study 17908974 — intervention group
Group type: COMPARATOR
Intervention: docetaxel + placebo
Number of subjects: 144
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementing written trial information with an explanation
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Description of a treatment as new
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor's uncertainty about the best treatment
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Random allocation suggestion by a doctor
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Justification for random allocation
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Active processing of trial information
Number of subjects: 9
Study 15763039 — intervention group
Group type: EXPERIMENTAL
Intervention: Current best practice in trial information
Number of subjects: 9
Study 11426168 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 degrees wedged cages
Number of subjects: 40
Study 11426168 — intervention group
Group type: COMPARATOR
Intervention: Rectangular cages
Number of subjects: 40
Study 9713140 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg, single dose)
Number of subjects: 82
Study 9713140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 8276209 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 12
Study 8276209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 12
Study 8276209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2659288 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 157
Study 2659288 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 157
Study 2659288 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam-aminoglycoside combination
Number of subjects: 157
Study 31505665 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (2 × 10^7 pfu)
Number of subjects: 1197
Study 31505665 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (1 × 10^8 pfu)
Number of subjects: 1197
Study 31505665 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSVΔG-ZEBOV-GP (all groups)
Number of subjects: 1197
Study 31505665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1197
Study 28780550 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-stage, multifaceted organisational intervention including data reviews, education, and facilitated action planning.
Number of subjects: 1289
Study 26291917 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 26291917 — intervention group
Group type: COMPARATOR
Intervention: Anal sphincter exercises with biofeedback
Number of subjects: 0
Study 26291917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (educational pamphlet)
Number of subjects: 0
Study 26291917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24176804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 0
Study 24176804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy‐cognitive
Number of subjects: 0
Study 24176804 — intervention group
Group type: EXPERIMENTAL
Intervention: Written accounts
Number of subjects: 0
Study 24176804 — intervention group
Group type: COMPARATOR
Intervention: Pre‐treatment AS
Number of subjects: 0
Study 24176804 — intervention group
Group type: COMPARATOR
Intervention: Pre‐treatment AS dimensions
Number of subjects: 0
Study 21613029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical barrier (2 mm obturation removed)
Number of subjects: 70
Study 21613029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical barrier (3 mm obturation removed)
Number of subjects: 70
Study 21613029 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 70
Study 21613029 — intervention group
Group type: COMPARATOR
Intervention: Gutta‐percha only (positive control)
Number of subjects: 70
Study 21613029 — intervention group
Group type: COMPARATOR
Intervention: Completely impermeabilized (negative control)
Number of subjects: 70
Study 19453313 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (25 mg)
Number of subjects: 40
Study 19453313 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (2.5 mg)
Number of subjects: 40
Study 16685054 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg/d)
Number of subjects: 430
Study 16685054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 15513235 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning signals contingent with the reaction stimuli
Number of subjects: 68
Study 15513235 — intervention group
Group type: COMPARATOR
Intervention: Erratic and irrelevant signals
Number of subjects: 68
Study 11321641 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective orienting task
Number of subjects: 0
Study 11321641 — intervention group
Group type: COMPARATOR
Intervention: Non-affective orienting task
Number of subjects: 0
Study 9625272 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg [14C]-labelled Losigamone
Number of subjects: 5
Study 9625272 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of each of the unlabelled enantiomers
Number of subjects: 5
Study 9625272 — intervention group
Group type: EXPERIMENTAL
Intervention: Losigamone
Number of subjects: 5
Study 7519696 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 7519696 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (verapamil and diltiazem)
Number of subjects: 0
Study 7519696 — intervention group
Group type: COMPARATOR
Intervention: First-generation dihydropyridines
Number of subjects: 0
Study 7519696 — intervention group
Group type: COMPARATOR
Intervention: Calcium-channel blockers
Number of subjects: 0
Study 3261159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 100
Study 3261159 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 100
Study 29322504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted group
Number of subjects: 218
Study 29322504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 218
Study 28889167 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention (45-minute interactive instructor-led session and 45-minute audio session)
Number of subjects: 25
Study 28889167 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention
Number of subjects: 25
Study 25578351 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser lithotripsy (LL)
Number of subjects: 982
Study 25578351 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic lithotripsy (PL)
Number of subjects: 982
Study 24298801 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified single length technique with Mtwo instrument (Group M)
Number of subjects: 265
Study 24298801 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified step‐back technique with Gates‐Glidden bur (Group G)
Number of subjects: 265
Study 24298801 — intervention group
Group type: COMPARATOR
Intervention: Step‐back technique with stainless steel H‐files (Group H)
Number of subjects: 265
Study 21164018 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-variable MDRD equation (4V-MDRDE)
Number of subjects: 0
Study 21164018 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-variable MDRD equation (6V-MDRDE)
Number of subjects: 0
Study 21164018 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRD equations (4V-MDRDE and 6V-MDRDE)
Number of subjects: 0
Study 18804142 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation F4 (combination of vitamins A, C, E and SCE)
Number of subjects: 0
Study 18804142 — intervention group
Group type: COMPARATOR
Intervention: Formulation F1 (vehicle)
Number of subjects: 0
Study 18804142 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation F3 (SCE)
Number of subjects: 0
Study 18804142 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation F4 (combination of vitamins and SCE)
Number of subjects: 0
Study 17063290 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 66
Study 17063290 — intervention group
Group type: COMPARATOR
Intervention: Open retro-rectus mesh repair
Number of subjects: 66
Study 12170407 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding 4 hours after ES
Number of subjects: 146
Study 12170407 — intervention group
Group type: COMPARATOR
Intervention: Refeeding 24 hours after ES
Number of subjects: 146
Study 10436310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose n-3 fatty acids (330 mg/day docosahexaenoic acid and 630 mg/day eicosapentanoic acid)
Number of subjects: 18
Study 10436310 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 18
Study 7788823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (OND) 0.1 mg.kg-1
Number of subjects: 233
Study 7788823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ondansetron (OND)
Number of subjects: 233
Study 7788823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 233
Study 2177861 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin 2500 UI anti‐Xa once daily
Number of subjects: 40
Study 2177861 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 UI twice daily
Number of subjects: 40
Study 378313 — intervention group
Group type: EXPERIMENTAL
Intervention: Brush cytology before biopsy
Number of subjects: 324
Study 378313 — intervention group
Group type: COMPARATOR
Intervention: Biopsy alone
Number of subjects: 324
Study 378313 — intervention group
Group type: COMPARATOR
Intervention: Cytology alone
Number of subjects: 324
Study 6621809 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory vestibular‐proprioceptive stimulation provided by waterbed flotation
Number of subjects: 20
Study 6621809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 30850023 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stenting
Number of subjects: 480
Study 30850023 — intervention group
Group type: COMPARATOR
Intervention: Deferred stenting (scheduled 4-10 days after primary angioplasty)
Number of subjects: 480
Study 30470853 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (PMX)
Number of subjects: 194
Study 30470853 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 194
Study 26672127 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5)
Number of subjects: 37
Study 26672127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37
Study 26672127 — intervention group
Group type: COMPARATOR
Intervention: meloxicam and placebo
Number of subjects: 37
Study 25232839 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/d cholecalciferol
Number of subjects: 137
Study 25232839 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d cholecalciferol (control)
Number of subjects: 137
Study 25232839 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (1200 IU/d and 400 IU/d)
Number of subjects: 137
Study 23171610 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT
Number of subjects: 10
Study 23171610 — intervention group
Group type: EXPERIMENTAL
Intervention: HIAT
Number of subjects: 10
Study 23171610 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT
Number of subjects: 10
Study 20187899 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA) peels
Number of subjects: 0
Study 20187899 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino fruit acid (AFA) peels
Number of subjects: 0
Study 17585872 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention prior to forensic medical examination
Number of subjects: 140
Study 17585872 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 140
Study 15653010 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 80 mg twice daily for 12 months
Number of subjects: 76
Study 15653010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 12184902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic (US) operative technique
Number of subjects: 59
Study 12184902 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery (ELC) operative technique
Number of subjects: 59
Study 12184902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 59
Study 12184902 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery (ELC)
Number of subjects: 59
Study 10660871 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin (CHO) at a dosage of 0.7 g.kg body mass‐1
Number of subjects: 6
Study 10660871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 6
Study 7607967 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 115
Study 2220651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (n = 124)
Number of subjects: 847
Study 2220651 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 221)
Number of subjects: 847
Study 2220651 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (n = 125)
Number of subjects: 847
Study 341998 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 14
Study 341998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30898826 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised public health approach to strengthen the management of LTBI, including contact measurement registries and regular in-service LTBI management training.
Number of subjects: 24
Study 30898826 — intervention group
Group type: COMPARATOR
Intervention: Usual LTBI care with no explicit evaluation, strengthening or training activities.
Number of subjects: 24
Study 27624505 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 59
Study 27624505 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 59
Study 25469738 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA) using a 3.5‐mm open‐irrigated‐tip (OIT) catheter with contact force measurement capabilities
Number of subjects: 99
Study 25469738 — intervention group
Group type: COMPARATOR
Intervention: Standard OIT catheters
Number of subjects: 99
Study 23383037 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 300 mg tenofovir disoproxil fumarate
Number of subjects: 144
Study 23383037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal 1% tenofovir gel (40 mg)
Number of subjects: 144
Study 21148030 — intervention group
Group type: EXPERIMENTAL
Intervention: cinacalcet plus low‐dose vitamin D sterols (30‐180 mg/day and ≤ 2 μg paricalcitol equivalent/dialysis)
Number of subjects: 360
Study 21148030 — intervention group
Group type: COMPARATOR
Intervention: flexible vitamin D therapy
Number of subjects: 360
Study 19527191 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (6 mg/24 h)
Number of subjects: 0
Study 19527191 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (12 mg/24 h)
Number of subjects: 0
Study 19527191 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (6 mg/24 h and 12 mg/24 h)
Number of subjects: 0
Study 17242247 — intervention group
Group type: EXPERIMENTAL
Intervention: New calcifications classified as BI-RADS category 2 (n = 40/68; 59%) and category 3 (n = 19/68; 28%)
Number of subjects: 402
Study 17242247 — intervention group
Group type: EXPERIMENTAL
Intervention: New calcifications classified as BI-RADS category 4 or 5 (n = 9/68; 13%)
Number of subjects: 402
Study 17242247 — intervention group
Group type: EXPERIMENTAL
Intervention: Median rate of development of benign calcifications
Number of subjects: 402
Study 17242247 — intervention group
Group type: EXPERIMENTAL
Intervention: Median rate of development of malignant calcifications
Number of subjects: 402
Study 17242247 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of new calcifications
Number of subjects: 402
Study 15497546 — intervention group
Group type: EXPERIMENTAL
Intervention: Series 10,000 machine
Number of subjects: 100
Study 15497546 — intervention group
Group type: COMPARATOR
Intervention: Diplomax machine
Number of subjects: 100
Study 12225701 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of ethanol
Number of subjects: 40
Study 12225701 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study 12225701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress task
Number of subjects: 40
Study 9447863 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.04 mg/kg)
Number of subjects: 60
Study 9447863 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (0.5 mg/kg)
Number of subjects: 60
Study 9447863 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (1.5 microg/kg)
Number of subjects: 60
Study 9447863 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study 8523623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (OX) plus a high caloric food supplement
Number of subjects: 271
Study 8523623 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo and a low calorie supplement
Number of subjects: 271
Study 2191938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (10-20 mg t.i.d., according to body weight)
Number of subjects: 37
Study 2191938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 375121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g L-dopa + 200 mg carbodopa per day orally for 30 days
Number of subjects: 6
Study 375121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g L-dopa + 200 mg carbodopa + 300 mg imipramine orally for 30 days
Number of subjects: 6
Study 375121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg apomorphine s.c. for 15 days
Number of subjects: 6
Study 375121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg apomorphine s.c. + 2 g L-dopa + 200 mg carbodopa per os daily for 15 days
Number of subjects: 6
Study 375121 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 6
Study 375121 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 6
Study 31831202 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Number of subjects: 20
Study 31831202 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 31351492 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified minimally invasive non-surgical therapy (MINST)
Number of subjects: 66
Study 31351492 — intervention group
Group type: COMPARATOR
Intervention: Modified minimally invasive surgical therapy (M-MIST)
Number of subjects: 66
Study 29850491 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine Dipeptide (GDP) supplementation (20 g/day for 7 days)
Number of subjects: 10
Study 29850491 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 10